Torrent Pharma's bid for Zentiva could be a step too far

On the face of it, Torrent Pharmaceutical's $2.5 billion bid for Sanofi's generic drug subsidiary Zentiva looks like a great deal for India’s 11^th largest pharma firm by market cap. Similar product portfolios, new market penetration in 50 countries home to a billion people and an established pharma player in Eastern Europe all points to a sure winner for Torrent.